⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RPRX News
Royalty Pharma plc Class A Ordinary Shares
Form 8-K
sec.gov
RPRX
Royalty Pharma reports second quarter 2026 results
globenewswire.com
RPRX
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
globenewswire.com
RPRX
Secretome Therapeutics Expands Rare Disease Leadership Team
businesswire.com
SRPT
RPRX
PFE
BIIB
GILD
AMGN
ATRA
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
globenewswire.com
RPRX
Royalty Pharma declares third quarter 2026 dividend
globenewswire.com
RPRX
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
globenewswire.com
RPRX
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
prnewswire.com
BIIB
RPRX
UCB
VTRS
NVS
KZR
GSK
AZN
ABBV
BMY
JNJ
mRNA Cancer Vaccine Market to Surpass $1.20 Billion in 2026 as Personalized Oncology Immunotherapies Advance, New Report Finds
globenewswire.com
MRNA
BNTX
ARCT
SANA
RPRX
Form 8-K
sec.gov
RPRX